Family Med Medical News about pregabalin benzodiazepine insomnia GAD

Become a Member Today!
Register

Most Viewed Abstracts

1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

2. Omega-3 fatty acids for bipolar disorder

3. Is folic acid good for everyone

4. ACS Releases Guidelines for HPV Vaccination

5. Vitamin D - A review Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia
International Clinical Psychopharmacology, 06/25/09

Montgomery SA et al. - Pregabalin was well tolerated, and improved overall anxiety symptoms, while specifically improving insomnia in patients with generalized anxiety disorder presenting with high levels of concurrent insomnia.

Methods

Pooled data were analyzed from six double-blind, placebo-controlled, 4- to 6-week trials of outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (fourth edition) criteria for GAD with a minimum Hamilton Rating Scale for Anxiety (HAM-A) score = 18.
Response was evaluated for three fixed-dose PGB groups (150, 300-450, 600 mg/day), and for a benzodiazepine group (alprazolam or lorazepam).
A 'high-insomnia' subgroup was defined by a baseline HAM for Depression (HAM-D) insomnia factor score greater than 3 (maximum = 6).

Results

At baseline, 1002 (54%) patients met the criteria for the high-insomnia subgroup, and 852 (46%) for the low-insomnia subgroup.
Mean baseline HAM-A scores were 1-2 points higher in high-insomnia versus low-insomnia patients.
In high-insomnia patients, PGB produced significantly greater improvement in HAM-A total scores at last observation carried forward endpoint on 300-450 mg (-13.1±0.6) and 600 mg (-11.2±0.5) dose groups compared with placebo (-8.3±0.5; P<0.0001 for both comparisons)
Improvement on PGB 150 mg was not significant (-9.9±0.7; P = 0.051).
Improvement was significant in the benzodiazepine group (-11.0±0.6; P<0.0001).
In the high-insomnia subgroup, treatment with PGB significantly (P<0.001) improved the HAM-D insomnia factor scores on both the 300-450 mg (-2.73) and 600 mg (-2.35) doses, and on benzodiazepines (-2.52) compared with placebo (-1.51)
Improvement on PGB 150 mg (-1.69) was not significant.
Rates of treatment-emergent insomnia were lower on PGB compared with placebo in both the high- and low-insomnia subgroups.

<< Previous
Poor vitamin C status is associated with increased carotid...

Next >>
Adverse effects of androgen deprivation therapy in prostate...

Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes
Journal of Clinical Oncology, 11/12/09 Relevance Score: 46%

Examining maladaptive beliefs about sleep across insomnia patient groups
Journal of Psychosomatic Research, 11/09/09 Relevance Score: 46%

Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
Diabetic Medicine, 10/01/09 Relevance Score: 45%

Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings
Rheumatology International, 10/08/09 Relevance Score: 44%

Computer Based Synchronization Analysis on Sleep EEG in Insomnia
The Journal of Medical Systems, 10/26/09 Relevance Score: 43%